Caveat creator: GenAI giants’ pledges won’t pre-empt copyright suits

Tech vendors offer indemnities on generative output, but end-users need to check the fine print, warn IP lawyers

One year after Wall Street banned the use of generative artificial intelligence (GenAI) bots, the prevailing defensive stance towards the technology has shifted to one of active exploration.

Even banks – known for their conservatism and risk aversion – are now racing to experiment with hundreds of use cases. Some are already opening up access to GenAI’s possibilities to large numbers of employees.

But in the midst of this boom, one question has become a persistently worrisome part of the

Only users who have a paid subscription or are part of a corporate subscription are able to print or copy content.

To access these options, along with all other subscription benefits, please contact info@waterstechnology.com or view our subscription options here: http://subscriptions.waterstechnology.com/subscribe

You are currently unable to copy this content. Please contact info@waterstechnology.com to find out more.

Sorry, our subscription options are not loading right now

Please try again later. Get in touch with our customer services team if this issue persists.

New to Waterstechnology? View our subscription options

The IMD Wrap: Will banks spend more on AI than on market data?

As spend on generative AI tools exceeds previous expectations, Max showcases one new tool harnessing AI to help risk and portfolio managers better understand data about their investments—while leaving them always in control of any resulting decisions.

You need to sign in to use this feature. If you don’t have a WatersTechnology account, please register for a trial.

Sign in
You are currently on corporate access.

To use this feature you will need an individual account. If you have one already please sign in.

Sign in.

Alternatively you can request an individual account here